Sangamo's Fabry Gene Therapy May Be A STAAR In The Making
Looks To Challenge Enzyme Replacement Therapy Biweekly Infusions
Executive Summary
The US biotech has presented interesting preliminary data from the first four patients treated in the Phase I/II STAAR study evaluating isaralgagene civaparvovec for Fabry.